Success Metrics

Clinical Success Rate
100.0%

Based on 25 completed trials

Completion Rate
100%(25/25)
Active Trials
0(0%)
Results Posted
20%(5 trials)

Phase Distribution

Ph phase_2
4
15%
Ph phase_4
1
4%
Ph early_phase_1
5
19%
Ph phase_1
10
37%
Ph phase_3
1
4%
Ph not_applicable
6
22%

Phase Distribution

15

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution27 total trials
Early Phase 1First-in-human
5(18.5%)
Phase 1Safety & dosage
10(37.0%)
Phase 2Efficacy & side effects
4(14.8%)
Phase 3Large-scale testing
1(3.7%)
Phase 4Post-market surveillance
1(3.7%)
N/ANon-phased studies
6(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

25 of 25 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

27

all time

Status Distribution
Active(2)
Completed(25)

Detailed Status

Completed25
Enrolling by invitation1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 15 (18.5%)
Phase 110 (37.0%)
Phase 24 (14.8%)
Phase 31 (3.7%)
Phase 41 (3.7%)
N/A6 (22.2%)

Trials by Status

completed2593%
enrolling_by_invitation14%
not_yet_recruiting14%

Recent Activity

0 active trials
Showing 5 of 27
not_yet_recruitingphase_2

Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use

NCT07452146
enrolling_by_invitationphase_2

Effects of Bronchial Segmental Endotoxin Instillation in Humans

NCT02392442
completedphase_1

Sleep and Healthy Aging Research on Depression for Younger Women

NCT03848715
completedphase_1

Aging and Reward System Response to Inflammation and Anxiety Study

NCT05363527
completedphase_2

Effect of Endotoxin on Alcohol Consumption

NCT04527185
View all 27 trials

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT07452146Phase 2

Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use

Not Yet Recruiting
NCT02392442Phase 2

Effects of Bronchial Segmental Endotoxin Instillation in Humans

Enrolling By Invitation
NCT03848715Phase 1

Sleep and Healthy Aging Research on Depression for Younger Women

Completed
NCT05363527Phase 1

Aging and Reward System Response to Inflammation and Anxiety Study

Completed
NCT04527185Phase 2

Effect of Endotoxin on Alcohol Consumption

Completed
NCT04310423Phase 2

An Inflammatory Challenge Using Endotoxin

Completed
NCT03256760Phase 1

Sleep and Healthy Aging Research for Depression (SHARE-D) Study

Completed
NCT01846559Phase 4

The Antiplatelet and Immune Response Trial

Completed
NCT02270619Early Phase 1

Sleep Health, Inflammation, and Emotion Study

Completed
NCT03083171Phase 1

Adrecizumab-LPS Study

Completed
NCT00094406Phase 1

Carbon Monoxide to Prevent Lung Inflammation

Completed
NCT03551184Not Applicable

Inflammation and Brain Function - Main Study

Completed
NCT00923910Phase 1

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

Completed
NCT02789241Phase 1

Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans

Completed
NCT02629874Phase 1

PK/PD of EA-230 During Endotoxemia

Completed
NCT01592526Early Phase 1

Autonomic Nervous Activity During the Systemic Inflammatory Response in Trained and Untrained Healthy Volunteers

Completed
NCT02127749Not Applicable

The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia

Completed
NCT01349699Not Applicable

Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia

Completed
NCT02529592Not Applicable

Endotoxin-induced Inflammatory and Behavioral Responses and Predictors of Individual Differences

Completed
NCT01766414Phase 3

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II

Completed

Drug Details

Intervention Type
DRUG
Total Trials
27